Sleep Risk Assessment and Clinical Management of Chronic Pain

2021 ◽  
Vol 37 (5) ◽  
pp. 1-7
Author(s):  
Anitha Saravanan
Pain ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Bethea A. Kleykamp ◽  
Robert H. Dworkin ◽  
Dennis C. Turk ◽  
Zubin Bhagwagar ◽  
Penney Cowan ◽  
...  

2014 ◽  
Vol 11 (5) ◽  
pp. 260-271 ◽  
Author(s):  
Kate A. McBride ◽  
Mandy L. Ballinger ◽  
Emma Killick ◽  
Judy Kirk ◽  
Martin H. N. Tattersall ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e017283 ◽  
Author(s):  
Emili Vela ◽  
Ákos Tényi ◽  
Isaac Cano ◽  
David Monterde ◽  
Montserrat Cleries ◽  
...  

BackgroundClinical management of patients with chronic obstructive pulmonary disease (COPD) shows potential for improvement provided that patients’ heterogeneities are better understood. The study addresses the impact of comorbidities and its role in health risk assessment.ObjectiveTo explore the potential of health registry information to enhance clinical risk assessment and stratification.DesignFixed cohort study including all registered patients with COPD in Catalonia (Spain) (7.5 million citizens) at 31 December 2014 with 1-year (2015) follow-up.MethodsA total of 264 830 patients with COPD diagnosis, based on the International Classification of Diseases (Ninth Revision) coding, were assessed. Performance of multiple logistic regression models for the six main dependent variables of the study: mortality, hospitalisations (patients with one or more admissions; all cases and COPD-related), multiple hospitalisations (patients with at least two admissions; all causes and COPD-related) and users with high healthcare costs. Neither clinical nor forced spirometry data were available.ResultsMultimorbidity, assessed with the adjusted morbidity grouper, was the covariate with the highest impact in the predictive models, which in turn showed high performance measured by the C-statistics: (1) mortality (0.83), (2 and 3) hospitalisations (all causes: 0.77; COPD-related: 0.81), (4 and 5) multiple hospitalisations (all causes: 0.80; COPD-related: 0.87) and (6) users with high healthcare costs (0.76). Fifteen per cent of individuals with highest healthcare costs to year ratio represented 59% of the overall costs of patients with COPD.ConclusionsThe results stress the impact of assessing multimorbidity with the adjusted morbidity grouper on considered health indicators, which has implications for enhanced COPD staging and clinical management.Trial registration numberNCT02956395.


2014 ◽  
Vol 10 (5) ◽  
pp. 353 ◽  
Author(s):  
Ted Jones, PhD ◽  
Samantha Lookatch, MA ◽  
Patricia Grant, MS, ANP-C ◽  
Janice McIntyre, MS, ANP-C ◽  
Todd Moore, PhD

Opioids remain a common method of treating chronic pain conditions despite some controversy. In an effort to address some of the risks of opioid medications, opioid risk assessment has become a standard of care when opioids are used to treat a chronic pain condition. Research to date has found that clinical interviews may be superior to currently available patient-completed written questionnaires in identifying patients likely to engage in medication aberrant behavior. The Brief Risk Interview (BRI) has been developed as a risk assessment tool that has the sensitivity of a clinical interview while eliminating the need for the lengthy process of an interview. The current study compared the predictive ability of the BRI with two commonly used patient-completed risk assessment tools: the Opioid Risk Tool (ORT) and the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R). After clinical staff at a pain practice underwent a 1-hour training program, 124 consecutive new patients were evaluated using the BRI, ORT, and SOAPP-R. Follow-up data found that the BRI was a good predictor of medication aberrant behavior and offered better sensitivity and better overall predictive accuracy than the ORT or the SOAPP-R. Overall, it appears that the BRI is a valid risk assessment tool that, after a brief training session, can be used effectively by pain clinicians. Further study is needed in other practice settings and with larger sample sizes.


2002 ◽  
Vol 76 (S2) ◽  
pp. 228-238 ◽  
Author(s):  
John M. Bennett ◽  
Peter A. Kouides ◽  
Stephen J. Forman

Author(s):  
Anthony W. Bateman ◽  
Roy Krawitz

Chapter 3 focuses on structured clinical management (SCM) as a treatment for borderline personality disorder (BPD). It describes the structure, pathway to assessment, process of assessment and diagnosis, crisis planning (including risk assessment, legal aspects, clinician and patient responsibilities, therapeutic alliance, substance abuse, stabilizing medication), and the treatment approach.


2012 ◽  
Vol 8 (5) ◽  
pp. 273-284 ◽  
Author(s):  
Gregory D. Salinas, PhD ◽  
Debi Susalka, BS ◽  
Stephen Burton, MS ◽  
Nancy Roepke, MBA ◽  
Kimberly Evanyo, BA ◽  
...  

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. 15-23 ◽  
Author(s):  
Anna Michelotti ◽  
Marco Invernizzi ◽  
Gianluca Lopez ◽  
Daniele Lorenzini ◽  
Francesco Nesa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document